Abstract:BACKGROUND/AIMS:Numerous studies have shown that NIMA-related kinase 2 (NEK2) expression in hepatocellular carcinoma (HCC) tissue is associated with survival and clinicopathological features; however, the evidence remains inconclusive. Thus, we aimed to further explore the prognostic and clinicopathological significance of NEK2 expression in HCC using a two-part study consisting of a retrospective cohort study and a meta-analysis. METHODS:In the cohort study, NEK2 expression in 206 HCC samples and adjacent normal liver tissues was detected by immunohistochemistry (IHC). Patients were divided into a high NEK2 expression group and a low NEK2 expression group by the median value of the immunohistochemical scores. The Kaplan-Meier method with the log-rank test was used to analyze survival outcomes in the two groups, and multivariate analysis based on Cox proportional hazard regression models was applied to identify independent prognostic factors. In the meta-analysis, eligible studies were searched in PubMed, EMBASE, Web of Science, and CNKI databases. STATA version 12.0 (Stata Corporation, College Station, TX) was used for statistical analyses. RESULTS:The IHC results of our cohort study showed higher NEK2 expression in HCC tissues compared with adjacent normal liver tissues. Multivariate analysis revealed that high NEK2 expression was an independent risk factor for poor overall survival (OS) [hazard ratio (HR) = 1.763; 95% CI, 1.060-2.935; P = 0.029] and disease-free survival (DFS) [hazard ratio (HR) = 1.687; 95% CI, 1.102-2.584; P = 0.016] in HCC patients. A total of 11 studies with 1,698 patients were enrolled in the meta-analysis, consisting of 10 studies from the database search and our cohort study. The pooled results revealed that high NEK2 expression correlated closely with poor OS among HCC patients (HR = 1.47; 95% CI, 1.21-1.80; P < 0.01), and DFS/recurrence-free survival (RFS) (HR = 1.92; 95% CI, 1.41-2.63; P < 0.01). Additionally, our meta-analysis also showed that the proportion of HCC patients with high NEK2 expression was greater in the group with larger tumors (> 5 cm) than in the group with smaller tumors (≤ 5 cm) [odds ratio (OR) = 2.02; 95% CI, 1.13-3.64; P < 0.01). CONCLUSION:Our study demonstrated that high NEK2 expression is a risk factor for poor survival in HCC patients. More prospective, homogeneous, and multiethnic studies are required to validate our findings.

NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis

Prognostic significance of NEK2 in human solid tumors: a systematic review and meta-analysis.

The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study.

Overexpression of NIMA-related Kinase 2 is Associated with Progression and Poor Prognosis of Prostate Cancer

Aberrant expression of NEK2 and its clinical significance in non-small cell lung cancer

Clinical Relevance and Prognostic Value of the Neuronal Protein Neuroligin 2 in Breast Cancer

Analysis of the effect of NEKs on the prognosis of patients with non-small-cell lung carcinoma based on bioinformatics

Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis

EXPRESSION OF NEK2 IN HEPATOCELLULAR CARCINOMA AND ITS RELATIONSHIP WITH CLINICAL PROGNOSIS

Role of NEK2 in tumorigenesis and tumor progression

NEK Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types

Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer

Integrative Analysis of the Expression Levels and Prognostic Values for NEK Family Members in Breast Cancer

Long Non-Coding RNA NEAT1 Overexpression is Associated with Poor Prognosis in Cancer Patients: a Systematic Review and Meta-Analysis

NEK2 Promotes Hepatocellular Carcinoma Migration and Invasion Through Modulation of the Epithelial-Mesenchymal Transition.

Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and meta-analysis

NEK2 Enhances Malignancies of Glioblastoma Via NIK/NF-κB Pathway.

Upregulation of NEK2 is Associated with Drug Resistance in Ovarian Cancer.

Prognostic value and immune infiltration of the NEK family in clear cell renal cell carcinoma

Low NDRG2 Expression Predicts Poor Prognosis in Solid Tumors

High NF-E2-related Factor 2 Expression Predicts Poor Prognosis in Patients with Lung Cancer: a Meta-Analysis of Cohort Studies.